Various NK cell-based cell therapy strategies are currently being evaluated for treatment of hematological malignancies and solid cancers.43–45 Much interest is directed toward transfusion of highly differentiated memory-like NK cells, but the field is still in its infancy.45–48 The findings in this study point toward a role also for more immature NKG2A-expressing NK cells. Here, KLRC1 is linked to hematologic disorder.